Chris Shibutani

“I'm struck by the ability to do several things at the same time while trying to realign your costs and integrate these businesses. There have been several advancements of timelines in terms of data readouts.”

“If I can ask a question on Mounjaro and the interplay with Trulicity. You've commented in the past that in terms of patients on Mounjaro, it has been about less than 10% on Trulicity.”

“Two questions, one on Paxlovid cross-currents there between China in terms of the million doses that you described for your first fiscal quarter and a potential transition into a private market in China, and then, U.S. where a similar transition will occur to the commercial.”

“One on the obesity opportunity for tirzepatide and the regulatory requirements there. SURMOUNT-3 and -4, I believe, are expected to complete also in the first half of next year.”

“On the business development, congratulations on the activity. Can you elaborate on what the decision would be for you to go ahead and acquire CBX-12? What kind of clinical data might you consider encouraging enough to advance that acquisition?”